The Department of Endocrinology, 
Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study.
- Dr. B. L. Kapur Super Speciality Hospital, New Delhi, India.
- Lady Hardinge Medical College & Smt. Sucheta Kriplani Hospital, New Delhi, India.
- Rajiv Gandhi Institute of Medical Sciences and RIMS Government General Hospital, Srikakulam, India.
- Popular Hospital, Varanasi, India.
- Getwell Hospital and Research Institute, Nagpur, India.
- Government Medical College, Kerala, India.
- Andhra Medical College, King George Hospital, Vishakhapatnam, India.
- Krishna Rajendra Hospital, Mysore Medical College & Research Institute, Mysore, India.
- BSES Municipal General Hospital, Mumbai, India.
- Om Surgical Center & Maternity Home, Varanasi, India.
- Christian Medical College, Vellore, India.
- Kasturba Medical College, Mangalore, India.
- SP Medical College and PBM Hospital, Bikaner, India.
- Sree Narayana Institute of Medical Sciences, Kochi, India.
- S.R. Kalla Memorial Gastro and General Hospital, Jaipur, India.
- Medipoint Hospitals Pvt Ltd, Pune, India.
- KRM Hospital and Research Centre, Lucknow, India.
- Lifepoint Multispecialty Hospital, Pune, India.
- Alkem Laboratories Ltd, Mumbai, India.
- Alkem Laboratories Ltd, Mumbai, India. Electronic address: publication@alkem.com.
Diabetes research and clinical practice Vol. 157 · pp. 107860
PMID 31526825 DOI 10.1016/j.diabres.2019.107860
Cite This Article
Ajay Kumar Ajmani, Aparna Agrawal, B L N Prasad, Indraneel Basu, Jayashree Shembalkar, Neeraj Manikanth, K A V Subrahmanyam, M Srinivasa, Manoj Chawla, Manoj Kumar Srivastava, Felix Jebasingh, Basavaprabhu Achappa, R P Agrawal, Rakesh K Pulichikkat, Ramdhan Meena, Shailaja Bhatia, Sandeep Kumar Gupta, Amol Dange, Ambrish Srivastava, Abhijit Trailokya, Vinayaka Shahavi, Sachin Shende. Efficacy and safety of evogliptin versus sitagliptin as an add-on therapy in Indian patients with type 2 diabetes mellitus inadequately controlled with metformin: A 24-week randomized, double-blind, non-inferiority, EVOLUTION INDIA study. Diabetes research and clinical practice. 2019;157:107860. doi:10.1016/j.diabres.2019.107860
Abstract
AIM: This study aimed to assess efficacy and safety of evogliptin versus sitagliptin, when added to background metformin therapy in Indian patients with uncontrolled type 2 diabetes.
METHOD: Overall, 184 patients with uncontrolled type 2 diabetes (7% ≤ HbA
RESULTS: Mean reductions in HbA1c at 12 weeks in evogliptin- and sitagliptin-treated patients were -0.37 (1.06) and -0.32 (1.14), respectively. The adjusted mean difference between treatment groups was -0.022 (95% CI: -0.374, 0.330; P = 0.901), that demonstrated non-inferiority. Reductions in FPG and PPG were similar between evogliptin and sitagliptin at 12 and 24 weeks. Changes in body weight were comparable between the treatment groups. Patients achieving target HbA
CONCLUSIONS: Evogliptin was non-inferior to sitagliptin in HbA reduction. It effectively improved glycemic control and was well tolerated in type 2 diabetes patients inadequately controlled by metformin alone.
Keywords
- Dipeptidyl peptidase-4 inhibitor
- Evogliptin
- Sitagliptin
- Type 2 diabetes mellitus
